Exploring biomarkers for cancer-related blood clots
Unveiling Prognosis Cancer-Associated Thromboembolism Biomarkers and Their Related Polymorphisms: Exploring Their Involvement With Immune Circulating Cells and Therapeutic Reversibility
PHASE1 · Lebanese University · NCT06065592
This study is testing if certain genetic markers and immune system interactions can help improve treatments for blood clots related to cancer, especially in colorectal cancer patients.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Lebanese University (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 2 sites (Tripoli, North Lebanon and 1 other locations) |
| Trial ID | NCT06065592 on ClinicalTrials.gov |
What this trial studies
This study investigates biomarkers and genetic variations associated with cancer-related thromboembolism, focusing on their interaction with the immune system. It aims to identify long non-coding RNAs and genes linked to the coagulation system, particularly in colorectal cancer, with plans to extend findings to other solid tumors. The study evaluates the potential of combining immunotherapy with targeted therapies and anticoagulants to improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals over 18 years old, of white ethnicity, diagnosed with early-stage colorectal cancer, and who have not received prior cancer therapies.
Not a fit: Patients with advanced cancer stages, previous cancer treatments, or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients suffering from cancer-associated thromboembolism.
How similar studies have performed: While the exploration of biomarkers in cancer-associated thromboembolism is gaining attention, this specific approach remains relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals of white ethnicity. * Age between \> 18 * Both males and females. * Diagnosis of selected cancer type (e.g., colorectal cancer). * Cancer stage 0/I/II without metastasis or lymph node dissemination at the time of enrollment. * No previous cancer therapy (radiotherapy, chemotherapy, or immunotherapy) received before study enrollment. * Unrelated patients. Exclusion Criteria: * Cancer stage III/IV. * History of hematological cancer types or previous cancers, recurrent or relapse. * Diagnosis of inflammatory bowel diseases. * Pre-existing cardiovascular diseases or coronary artery diseases. * Confirmed treated or untreated autoimmune diseases. * Metabolic disorders, diabetes, or hypertension. * Neurological diseases. * Evidence of cardiac, renal, bone, or cerebral damage. * Presence of more than one type of malignancies. * Active infections or myositis. * Familial polyposis. * Alcohol or smoking habits. * Colon-affecting food allergies. * Body mass index (BMI) \>30. * Significant weight loss within the last 2 years. * History of abdominal surgeries. * Pregnancy. * Related patients.
Where this trial is running
Tripoli, North Lebanon and 1 other locations
- Haykel Hospital — Tripoli, North Lebanon, Lebanon (RECRUITING)
- Lebanese University — Tripoli, North Lebanon, Lebanon (RECRUITING)
Study contacts
- Study coordinator: Nehman Makdissy, Professor
- Email: nehman.makdissy@ul.edu.lb
- Phone: +96171210250
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases, Immune System Diseases, Inflammatory Diseases, Colon Cancer, Breast Cancer